An in-depth look at this medical topic, providing essential context for patients and caregivers.
General Medical Overview
Pseudomyxoma peritonei: A condition categorized under Rare Abdominal & Miscellaneous.
Pseudomyxoma peritonei (PMP) is a rare condition characterized by progressive accumulation of mucinous tumor deposits throughout the peritoneal cavity, causing 'jelly belly.' It most commonly originates from a ruptured appendiceal mucinous neoplasm. PMP is treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) — a specialized procedure available at expert reference centers.
Typical Treatment Roadmap
Detection
Symptoms and initial checkup.
Diagnosis
Biopsy and clinical imaging.
Treatment
Therapy (Surgery, Chemo, etc.)
Monitoring
Follow-up and recovery.
Clinical Manifestation (Main Symptoms)
Clinically, the initial presentation of Pseudomyxoma peritonei often manifests with Fatigue, Weight Loss, Pain and Indigestion.
Advanced Stage Signs (Warning)
Progressive abdominal distension ('jelly belly'), increasing abdominal girth, ovarian masses (mistaken for ovarian cancer), hernia, and intestinal obstruction.
Diagnostic Procedures
CT showing mucinous ascites with peritoneal implants and appendiceal primary, tumor markers (CEA, CA19-9, CA-125), and histological grading (low-grade vs high-grade mucinous carcinoma peritonei).
Medical Risk Factors
Appendiceal mucinous neoplasm (primary cause). KRAS and GNAS mutations are common. No modifiable risk factors.
Therapeutic Approach
CRS (cytoreductive surgery — peritonectomy procedures removing all visible tumor) + HIPEC (heated intraperitoneal mitomycin C or oxaliplatin). Appendectomy/right hemicolectomy for the primary. Systemic chemotherapy (FOLFOX/capecitabine) for unresectable or recurrent disease.
Medical Breakthroughs & Hope
Specialized CRS + HIPEC centers have transformed PMP from an untreatable condition to one with meaningful long-term survival. Expert centers report excellent outcomes with acceptable morbidity from this complex but potentially curative procedure.
Prognosis & Efficacy82%
Low-grade PMP treated with CRS + HIPEC has 10-year survival of approximately 60-70%. High-grade mucinous carcinoma peritonei has approximately 20-30% 10-year survival. Complete cytoreduction (CC-0/CC-1) is the strongest prognostic factor.
Myth vs. Clinical Reality
Myth / Fiction
PMP from an appendix tumor is always fatal.
Fact / Reality
With modern CRS + HIPEC, 10-year survival for low-grade PMP exceeds 60-70%. This was a fatal condition just decades ago.
Myth / Fiction
HIPEC is experimental.
Fact / Reality
CRS + HIPEC is a well-established, guideline-recommended treatment for PMP performed at specialized centers worldwide since the 1990s.
Frequently Asked Questions (FAQ)
What causes 'jelly belly'?
Mucinous tumor cells produce copious amounts of gelatinous mucin that progressively fills the abdominal cavity, causing distension.
Is PMP the same as appendiceal cancer?
PMP is a syndrome caused by mucinous tumor spread from the appendix (usually) throughout the peritoneum. The appendix is the source, but PMP describes the peritoneal disease pattern.
What is HIPEC?
Hyperthermic intraperitoneal chemotherapy — heated chemotherapy solution (42°C) is circulated throughout the open abdomen after maximal tumor removal, killing microscopic residual cancer cells.
Do I need treatment at a specialized center?
Yes. CRS + HIPEC is a complex, multi-hour procedure requiring specialized surgical expertise. Outcomes are significantly better at high-volume reference centers.
Can it be cured?
Complete cytoreduction (removing all visible tumor) combined with HIPEC achieves long-term disease control in the majority of low-grade PMP patients, with many considered functionally cured.